Literature DB >> 22401150

Burden of illness for an employed population with chronic obstructive pulmonary disease.

Kavita Nair1, Vahram Ghushchyan, Jill Van Den Bos, Michael L Halford, Gideon Tan, Feride H Frech-Tamas, Joseph Doyle.   

Abstract

Chronic obstructive pulmonary disease (COPD) affects approximately 7% of Americans. COPD impacts productivity and forces 1 in 5 employees ages 45-65 years old to retire prematurely. Our objective was to quantify the direct and indirect costs of COPD in an employed population in the United States. A retrospective analysis using Thomson Reuters MarketScan commercial claims and Health and Productivity (HPM) databases (2000-2007) identified employees (ages 18-65 years) with ≥ 1 COPD medical claim, ≥ 6 month insurance eligibility pre and ≥ 12 months post diagnosis, and ≥ 12 months HPM data post diagnosis. COPD subjects were matched to non-COPD subjects using propensity scores to create a comparison group with similar characteristics. Differences in medical and pharmacy utilization and productivity (absence and short-term disability [STD] days) were examined using negative binomial regression, and cost differences using Heckman selection models. A total of 27,612 COPD patients were matched in a 1:1 ratio to 825,884 non-COPD patients; 80% were ages 36-65 years, and 59% were male. COPD employees had about twice the rate of emergency department visits and hospitalizations compared to non-COPD employees (P<0.0001). The rate of absence and STD days was approximately 1.5 times higher (P<0.0001) compared to non-COPD employees. Yearly direct and indirect expenditures were higher ($3609 and $909, respectively; P<0.0001) for COPD versus non-COPD employees. Excess utilization and associated costs of COPD to employers was quantified. By understanding these costs, employers may evaluate disease management programs and treatment to improve outcomes for employees with COPD. Improved treatment options may reduce the direct and indirect costs of COPD.

Entities:  

Mesh:

Year:  2012        PMID: 22401150     DOI: 10.1089/pop.2011.0049

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  7 in total

Review 1.  The global impact of non-communicable diseases on macro-economic productivity: a systematic review.

Authors:  Layal Chaker; Abby Falla; Sven J van der Lee; Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-04-03       Impact factor: 8.082

Review 2.  Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States.

Authors:  Jeetvan G Patel; Saurabh P Nagar; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-03-19

3.  Healthcare costs of patients with chronic obstructive pulmonary disease in Denmark - specialist care versus GP care only.

Authors:  Jesper Lykkegaard; Jesper Bo Nielsen; Maria Munch Storsveen; Dorte Ejg Jarbøl; Jens Søndergaard
Journal:  BMC Health Serv Res       Date:  2022-03-28       Impact factor: 2.655

4.  Economic burden of COPD in a Swedish cohort: the ARCTIC study.

Authors:  Karin Lisspers; Kjell Larsson; Gunnar Johansson; Christer Janson; Madlaina Costa-Scharplatz; Jean-Bernard Gruenberger; Milica Uhde; Leif Jorgensen; Florian S Gutzwiller; Björn Ställberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-01-11

5.  The unmet global burden of COPD.

Authors:  S A Quaderi; J R Hurst
Journal:  Glob Health Epidemiol Genom       Date:  2018-04-06

6.  The macroeconomic burden of noncommunicable diseases in the United States: Estimates and projections.

Authors:  Simiao Chen; Michael Kuhn; Klaus Prettner; David E Bloom
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

7.  COPD affects worker productivity and health care costs.

Authors:  Jeetvan G Patel; Anna D Coutinho; Orsolya E Lunacsek; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-07-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.